Last 48 quarters of trend data · Healthcare · Medical - Healthcare Information Services
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 18.44 | — | 11.79 | 128.13 | 41.87 | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 0.85 | 1.48 | 1.84 | 3.74 | 2.20 | 1.82 | 0.69 | 1.66 | 2.43 | 2.80 | 2.23 | 1.98 | 4.39 |
| — | -18.6% | +166.1% | +125.3% | -9.4% | -34.9% | -68.9% | -16.2% | -44.8% | -41.7% | -41.8% | -55.1% | -50.5% | |
| P/B Ratio | 0.74 | 0.91 | 1.85 | 3.19 | 2.15 | 1.38 | 0.77 | 1.24 | 1.51 | 1.80 | 2.00 | 1.11 | 2.10 |
| — | -33.9% | +142.1% | +158.1% | +42.6% | -23.6% | -61.7% | +10.9% | -28.0% | -10.7% | -16.2% | -45.8% | -40.5% | |
| P/FCF | 5.01 | — | 8.39 | 30.54 | 14.10 | 10.42 | 286.90 | 20.81 | 65.49 | 28.09 | — | 28.11 | — |
| — | — | -97.1% | +46.7% | -78.5% | -62.9% | — | -25.9% | — | — | — | +44.5% | — | |
| EV / EBITDA | 5.87 | 20.78 | 6.00 | 33.35 | 15.78 | — | 5.78 | — | — | — | — | — | — |
| — | — | +3.8% | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | 7.98 | 76.62 | 6.90 | 45.28 | 20.29 | — | 7.25 | — | — | — | — | — | — |
| — | — | -4.8% | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
OptimizeRx Corporation's operating margin was 2.0% in Q1 2026, down 25.7 pp QoQ and up 11.6 pp YoY. The trailing four-quarter average of 12.1% exceeds the current quarter, suggesting the latest result may reflect seasonal weakness or a one-off headwind. Gross margin expanded 14.8% YoY, indicating pricing power or improving input costs.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 63.3% | 69.9% | 74.8% | 67.2% | 63.8% | 60.9% | 68.1% | 63.1% | 62.2% | 62.0% | 62.9% | 60.0% | 56.6% |
| — | +14.8% | +9.7% | +6.5% | +2.6% | -1.8% | +8.4% | +5.2% | +9.9% | +8.4% | -0.8% | -3.9% | -11.9% | |
| Operating Margin | 11.0% | 2.0% | 27.7% | 7.9% | 10.9% | -9.6% | 11.2% | -40.2% | -19.9% | -25.5% | -38.4% | -21.8% | -35.1% |
| — | +120.7% | +146.5% | +119.6% | +154.8% | +62.3% | +129.3% | -84.7% | +43.2% | +53.0% | -773.9% | +12.6% | -25.5% | |
| Net Margin | 4.7% | -2.5% | 15.6% | 3.0% | 5.2% | -10.0% | -0.2% | -42.8% | -21.3% | -35.0% | -14.6% | -17.5% | -30.1% |
| — | +75.1% | +6550.4% | +107.0% | +124.6% | +71.4% | +98.3% | -144.1% | +29.2% | +28.8% | -780.6% | +23.7% | -8.4% |
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 4.2% | -0.4% | 4.0% | 0.6% | 1.3% | -1.9% | -0.1% | -7.7% | -3.3% | -5.5% | -3.4% | -2.5% | -3.5% |
| — | +79.6% | +6045.3% | +108.3% | +139.5% | +66.0% | +98.0% | -213.6% | +5.2% | -8.3% | -1239.1% | +3.7% | -21.4% | |
| ROA | 2.9% | -0.3% | 2.9% | 0.5% | 0.9% | -1.3% | -0.0% | -5.4% | -2.3% | -3.8% | -2.7% | -2.3% | -3.3% |
| — | +77.8% | +6331.5% | +108.5% | +139.6% | +66.2% | +98.3% | -131.0% | +30.2% | +20.2% | -1018.8% | +4.5% | -20.9% | |
| ROIC | 6.8% | 0.2% | 5.1% | 1.2% | 1.8% | -1.2% | 2.0% | -4.6% | -2.0% | -2.6% | -6.4% | -2.5% | -3.4% |
| — | +119.1% | +153.9% | +125.1% | +192.1% | +54.2% | +131.5% | -85.3% | +42.2% | +47.6% | -869.4% | +36.7% | +44.2% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
OptimizeRx Corporation's Debt/EBITDA ratio is 16.2x, up from 2.6x last quarter — elevated, raising questions about debt serviceability. The current ratio has improved 90.6% YoY to 5.37x, strengthening the short-term liquidity position. Debt/Equity has declined for 7 consecutive quarters, reflecting a deleveraging trend.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.20 | 0.18 | 0.20 | 0.23 | 0.24 | 0.28 | 0.28 | 0.31 | 0.30 | 0.30 | 0.29 | 0.00 | 0.00 |
| — | -35.1% | -28.3% | -25.0% | -18.5% | -5.2% | -2.5% | +24276.3% | +236560.3% | +17259.4% | +15552.3% | -34.8% | -93.6% | |
| Debt / EBITDA | 1.59 | 16.24 | 2.61 | 9.56 | 6.80 | — | 7.02 | — | — | — | — | — | — |
| — | — | -62.9% | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 3.04 | 5.37 | 3.04 | 3.05 | 2.57 | 2.82 | 2.89 | 3.23 | 3.07 | 2.88 | 3.04 | 11.35 | 15.44 |
| — | +90.6% | +5.2% | -5.7% | -16.4% | -2.3% | -4.8% | -71.5% | -80.1% | -77.1% | -74.1% | -29.9% | -9.9% | |
| Quick Ratio | 3.04 | 5.37 | 3.04 | 3.05 | 2.57 | 2.82 | 2.89 | 3.23 | 3.07 | 2.88 | 3.04 | 11.35 | 15.44 |
| — | +90.6% | +5.2% | -5.7% | -16.4% | -2.3% | -4.8% | -71.5% | -80.1% | -77.1% | -74.1% | -29.9% | -9.9% | |
| Interest Coverage | 2.28 | 0.34 | 7.02 | 1.91 | 2.07 | -1.53 | 2.41 | -5.52 | -2.34 | -3.24 | -5.65 | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying OPRX stock.
OptimizeRx Corporation's current P/E is 18.4x. The average P/E over the last 3 quarters is 60.6x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
OptimizeRx Corporation's current operating margin is 11.0%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking OptimizeRx Corporation's business trajectory between earnings reports.